TargetBeta
FGFR1
fibroblast growth factor receptor 1 · also H2, H3, H4, H5 · CD molecules
6 programs in company-led studies act on FGFR1, from 6 companies: 4 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | ChEMBL |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 761 running | FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB | ChEMBL |
| futibatinibrule | Otsuka | phase 3 | 104 running | FGFR2, FGFR3, FGFR4 | ChEMBL |
| infigratinibrule | BridgeBio | phase 3 | 173 running | FGFR2, FGFR3, FGFR4 | ChEMBL |
| pemigatinibrule | Incyte | phase 3 | 161 running | FGFR2, FGFR3 | NCIt |
| fanregratinibrule | HUTCHMED | phase 3 | 81 running | – | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Cholangiocarcinoma, 4 programs
- Neoplasms, 2 programs
- Stomach Neoplasms, 2 programs
- Achondroplasia, 1 program
- Adenocarcinoma Of Esophagus, 1 program
- Biliary Tract Neoplasms, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Carcinoma, Transitional Cell, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026futibatinib · Otsuka · phase 3 · NCT05727176
- Jan 2027infigratinib · BridgeBio · phase 3 · NCT06873035
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
- Jun 30, 2028fanregratinib · HUTCHMED · phase 3 · NCT04353375
- Nov 14, 2028nintedanib · Boehringer Ingelheim · phase 4 · NCT07335562
- Feb 25, 2031pemigatinib · Incyte · phase 3 · NCT07862998
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.